LICENSE, COLLABORATION AND OTHER REVENUE - Mitsubishi Tanabe Pharma Corporation Collaboration Agreement (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) performance_obligation	Jun. 30, 2022 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue	$ 56,376,000	$ 126,365,000	$ 96,381,000	$ 187,988,000
Other long-term liabilities	17,142,000	74,610,000	17,142,000	74,610,000	$ 16,772,000	$ 15,717,000	$ 83,141,000
Revenue recognized	0	15,503,000	0	22,105,000
Accounts receivable
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable	525,000	56,626,000	525,000	56,626,000		$ 1,901,000		$ 19,094,000
Mitsubishi Tanabe Pharma Corporation
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue			4,000,000
Mitsubishi Tanabe Pharma Corporation | License Collaboration And Other Revenue, Royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue	500,000	400,000	900,000	700,000
Mitsubishi Tanabe Pharma Corporation | Regulatory Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone revenue			$ 25,000,000
Mitsubishi Tanabe Pharma Corporation | Development And Commercialize Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of performance obligations | performance_obligation			2
Mitsubishi Tanabe Pharma Corporation | Development And Commercialize Collaboration Agreement | Regulatory Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone revenue			$ 15,000,000
Mitsubishi Tanabe Pharma Corporation | Development And Commercialize Research And License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront cash payment received			20,000,000
Cost of research services			20,500,000
Milestone revenue			10,000,000
Accounts receivable	0		0
Deferred revenue	0		0
Mitsubishi Tanabe Pharma Corporation | Development And Commercialize Research And License Agreement | Regulatory Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone revenue			10,000,000
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited | Accounts receivable
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable	0		0
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred revenue	0		0
Other long-term liabilities	0		0
Revenue recognized	0	$ 0	3,700,000	$ 7,600,000
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement | Accounts receivable
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up-front payments invoiced	$ 0		$ 0